--- title: "Optimi Health prices US IPO of 2,400,000 shares at US$6.25" url: "https://aibio.space/news/optimi-health-prices-us-ipo-2-400-000-shares-us-6-25/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-05-20" section: "Financings" tickers: "CSE:OPTI" source: "https://www.sec.gov/Archives/edgar/data/2027329/000119312526231760/d43258d424b4.htm" summary: "The offering totals US$15,000,000 before fees. Optimi has been approved to list on the Nasdaq Capital Market under the symbol OPTH." --- By the aibio.space news desk. Sources - [Optimi Health Corp. 424B4 (2026-05-20)](https://www.sec.gov/Archives/edgar/data/2027329/000119312526231760/d43258d424b4.htm) [OPTI](https://aibio.space/companies/optimi-health/) 2026-05-20 # Optimi Health prices US IPO of 2,400,000 shares at US$6.25 Tickers [OPTI](https://aibio.space/companies/optimi-health/) The offering totals US$15,000,000 before fees. Optimi has been approved to list on the Nasdaq Capital Market under the symbol OPTH. ## Key facts - **Company**: Optimi Health Corp. (CSE: OPTI) - **News type**: Financings - **Primary source**: [Optimi Health Corp. 424B4 (2026-05-20)](https://www.sec.gov/Archives/edgar/data/2027329/000119312526231760/d43258d424b4.htm) *A financial district skyline and bay. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* Optimi Health Corp. priced its initial public offering in the United States at US$6.25 a share, according to a prospectus dated May 19, 2026. The company is offering 2,400,000 common shares for gross proceeds of US$15,000,000. Underwriting discounts and commissions come to US$1,125,000, leaving US$13,875,000 to the company before expenses. The net proceeds after expenses are estimated at about US$12.2 million, or US$14.3 million if the underwriter exercises its over-allotment option in full. ## Who is selling the shares Joseph Gunnar & Co., LLC is the sole bookrunner. The underwriter has an option, exercisable for 45 days, to buy up to 360,000 more common shares to cover over-allotments. It expects to deliver the shares on or about May 21, 2026. Optimi is also registering warrants for the underwriter to buy up to 110,400 common shares, assuming the over-allotment option is exercised in full. Those warrants are priced at 120% of the initial offering price. Endeavor Trust Corporation is the transfer agent and registrar. ## The Nasdaq listing and the reverse split Optimi has been approved to list on the Nasdaq Capital Market under the symbol OPTH, and trading on the OTCQX will stop. Its board approved a 1-for-30 reverse share split, which took effect on May 19, 2026. The company says the split is intended to let it meet Nasdaq's minimum share price requirement. On May 15, 2026, the last reported sale price on the Canadian Securities Exchange was C$9.45. That is C$0.32 before the split. The filing also gives an OTCQX price of US$7.14, which it adjusts for the split as US$0.24 before the split. The shares remain listed in Canada as OPTI and in Germany on the Frankfurt Stock Exchange as 8BN. ## Losses and going-concern doubt The prospectus says the company has suffered recurring losses and has a net capital deficiency, and that these conditions raise substantial doubt about its ability to continue as a going concern. For the three months ended December 31, 2025, the net loss was C$1,553,975, or US$1,133,296. For the fiscal year ended September 30, 2025, the net loss was C$3,712,031, or US$2,665,349. The company says it has not yet achieved profitable operations and may not do so in the foreseeable future. ## What the company makes Optimi describes itself as a Canadian Good Manufacturing Practice compliant drug manufacturer, licensed by Health Canada to handle controlled substances. Its products are MDMA and psilocybin derived from botanical sources. It operates two production facilities of about 10,000 square feet each on leased land in Princeton, British Columbia, under a Drug Establishment Licence from Health Canada. The company's market access is limited. The prospectus says MDMA is in phase 2 trials conducted by third parties in Israel, which it calls a planned target market, and that access there is restricted to approved clinical trials. It also says the company is currently restricted from selling its products in the United States, another planned market, where psilocybin and MDMA are Schedule I substances. ## What the money is for The company plans to use the net proceeds to scale production and distribution in its current markets, expand into Israel and the United States, grow sales and fund working capital and other operating expenses. The summary of the offering does not give a split among those uses. ## Lock-up and status Directors, officers and certain shareholders have agreed with the underwriter, subject to certain exceptions, not to sell, transfer or dispose of their shares. The filing says the company is an emerging growth company and a foreign private issuer. That gives it reduced reporting requirements, and the prospectus warns that purchasers in the offering will face immediate and substantial dilution in the book value of their investment. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story OPTI Optimi Health Corp. CSE ยท Canada Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/optimi-health-prices-us-ipo-2-400-000-shares-us-6-25/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Optimi Health prices US IPO of 2,400,000 shares at US$6.25", 2026-05-20, https://aibio.space/news/optimi-health-prices-us-ipo-2-400-000-shares-us-6-25/